|
1
|
Ebrahimi A, Zhang WJ, Gao K and Clark JR:
Nodal yield and survival in oral squamous cancer: Defining the
standard of care. Cancer. 117:2917–2925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 22:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlsson J, Sundqvist P, Kosuta V, Fält A,
Giunchi F, Fiorentino M and Davidsson S: PD-L1 expression is
associated with poor prognosis in renal cell carcinoma. Appl
Immunohistochem Mol Morphol. 28:213–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pei R, Zhang W, Wang S, Huang X and Zou Y:
Prognostic value of PD-L1 in patients with hepatocellular
carcinoma. Clin Lab. May 1–2019.(Epub ahead of print). doi:
10.7754/Clin.Lab.2018.180839. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Webb JR, Milne K, Kroeger DR and Nelson
BH: PD-L1 expression is associated with tumor-infiltrating T cells
and favorable prognosis in high-grade serous ovarian cancer.
Gynecol Oncol. 141:293–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takada K, Toyokawa G, Shoji F, Okamoto T
and Maehara Y: The significance of the PD-L1 expression in
non-small-cell lung cancer: Trenchant double swords as predictive
and prognostic markers. Clin Lung Cancer. 19:120–129. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gheldof A, Hulpiau P, van Roy F, De Craene
B and Berx G: Evolutionary functional analysis and molecular
regulation of the ZEB transcription factors. Cell Mol Life Sci.
69:2527–2541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vandewalle C, Van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang PJ, Sun YT and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsutsumi S, Saeki H, Nakashima Y, Ito S,
Oki E, Morita M, Oda Y, Okano S and Maehara Y: Programmed
death-ligand 1 expression at tumor invasive front is associated
with epithelial-mesenchymal transition and poor prognosis in
esophageal squamous cell carcinoma. Cancer Sci. 108:1119–1127.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai
HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT and Chen CJ: High
PD-L1 expression correlates with metastasis and poor prognosis in
oral squamous cell carcinoma. PLoS One. 10:e01426562015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao X, Sun S, Zhou X, Zhang Q, Guo W and
Zhang L: Clinicopathological significance of ZEB-1 and E-cadherin
proteins in patients with oral cavity squamous cell carcinoma. Onco
Targets Ther. 10:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobin LH and Wittekind C: TNM
Classification of Malignant Tumours. 6th edition. John Wiley &
Sons Inc.; New York, USA: pp. 22–26. 2002
|
|
14
|
Jakobsson PA, Eneroth CM, Killander D,
Moberger G and Mårtensson B: Histologic classification and grading
of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys
Biol. 12:1–8. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Willén R, Nathanson A, Moberger G and
Anneroth G: Squamous cell carcinoma of the gingiva. Histological
classification and grading of malignancy. Acta Otolaryngol.
79:146–154. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto E, Miyakawa A and Kohama G: Mode
of invasion and lymph node metastasis in squamous cell carcinoma of
the oral cavity. Head Neck Surg. 6:938–947. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piffko J, Bánkfalvi A, Ofner D, Rasch D,
Joos U and Schmid KW: Standardized demonstration of silver-stained
nucleolar organizer regions-associated proteins in archival oral
squamous cell carcinomas and adjacent non-neoplastic mucosa. Mod
Pathol. 10:98–104. 1997.PubMed/NCBI
|
|
18
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chin D, Boyle GM, Williams RM, Ferguson K,
Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman
WB: Novel markers for poor prognosis in head and neck cancer. Int J
Cancer. 113:789–797. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Greaves P and Gribben JG: The role of B7
family molecules in hematologic malignancy. Blood. 121:734–744.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keir ME, Liang SC, Guleria I, Latchman YE,
Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe
AH: Tissue expression of PD-L1 mediates peripheral T cell
tolerance. J Exp Med. 203:883–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ
and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer
cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ohigashi Y, Sho M, Yamada Y, Tsurui Y,
Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strome SE, Dong H, Tamura H, Voss SG,
Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al:
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous
cell carcinoma. Cancer Res. 63:6501–6505. 2003.PubMed/NCBI
|
|
27
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wintterle S, Schreiner B, Mitsdoerffer M,
Schneider D, Chen L, Meyermann R, Weller M and Wiendl H: Expression
of the B7-related molecule B7-H1 by glioma cells: A potential
mechanism of immune paralysis. Cancer Res. 63:7462–7467.
2003.PubMed/NCBI
|
|
29
|
Ghebeh H, Mohammed S, Al-Omair A, Qattan
A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah
A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is
expressed in breast cancer patients with infiltrating ductal
carcinoma: Correlation with important high-risk prognostic factors.
Neoplasia. 8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thompson RH, Kuntz SM, Leibovich BC, Dong
H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H,
et al: Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res.
66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nomi T, Sho M, Akahori T, Hamada K, Kubo
A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and
Nakajima Y: Clinical significance and therapeutic potential of the
programmed death-1 ligand/programmed death-1 pathway in human
pancreatic cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L, Xu LJ, Zhu J, Li J, Xue BX, Gao
J, Sun CY, Zang YC, Zhou YB, Yang DR and Shan YX: ATM-JAK-PD-L1
signaling pathway inhibition decreases EMT and metastasis of
androgen-independent prostate cancer. Mol Med Rep. 17:7045–7054.
2018.PubMed/NCBI
|
|
33
|
Ran J, Lin DL, Wu RF, Chen QH, Huang HP,
Qiu NX and Quan S: ZEB1 promotes epithelial-mesenchymal transition
in cervical cancer metastasis. Fertil Steril. 103:1606–1614.e2.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mock K, Preca BT, Brummer T, Brabletz S,
Stemmler MP and Brabletz T: The EMT-activator ZEB1 induces bone
metastasis associated genes including BMP-inhibitors. Oncotarget.
6:14399–14412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurahara H, Takao S, Maemura K, Mataki Y,
Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, et al:
Epithelial-mesenchymal transition and mesenchymal-epithelial
transition via regulation of ZEB-1 and ZEB-2 expression in
pancreatic cancer. J Surg Oncol. 105:655–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hashiguchi M, Ueno S, Sakoda M, Iino S,
Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et
al: Clinical implication of ZEB-1 and E-cadherin expression in
hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
|
